Journal of Pharmaceutical Research International

34(30B): 21-24, 2022; Article no.JPRI.85930
ISSN: 2456-9119
(Past name: British Journal of Pharmaceutical Research, Past ISSN: 2231-2919, NLM ID: 101631759)

Low HDL Levels as a Major Risk Factor of Acute Myocardial Infarction in Pakistani Old Age Population

Hafiza Maryam Mushtaq [a*], Zaryab Ali [b], Kinza Zafar [b] and Muhammad Zarrar Arif Butt [c]

[a] *Ghazi Khan Medical College, Pakistan.*
[b] *DHQ Hafizabad, Pakistan.*
[c] *Fatima Memorial Hospital, Lahore, Pakistan.*

Authors' contributions

This work was carried out in collaboration among all authors. All authors read and approved the final manuscript.

Article Information

DOI: 10.9734/JPRI/2022/v34i30B36075

Open Peer Review History:
This journal follows the Advanced Open Peer Review policy. Identity of the Reviewers, Editor(s) and additional Reviewers, peer review comments, different versions of the manuscript, comments of the editors, etc are available here: https://www.sdiarticle5.com/review-history/85930

Original Research Article

Received 28 January 2022
Accepted 07 April 2022
Published 12 April 2022

ABSTRACT

Introduction: Cardiovascular disease (CVD) is the main source of death around the world, which has turned into an overall general medical condition. Acute myocardial infarction (AMI) is a typical clinical basic disease.
Objective: The basic aim of the study is to analyse the low high density lipoprotein (HDL) levels as a major risk factor of acute myocardial infarction in Pakistan.
Materials and Methods: This cross sectional study was conducted in Ghazi Khan Medical College and DHQ Hafizabad between June and November 2021, according to the ethical committee of the hospital. The data was collected from 100 patients of both genders.
Results: The mean age was 45±5.46 years. The extent of male subjects was higher in bunches with high Triglycerides (TG) levels, while the distinction in age was not measurably critical.
Conclusion: It is concluded that low HDL level is noted to be present in a high percentage of acute myocardial infarction patients and can be a major risk contributor to old age patients.

Keywords: Low HDL levels; acute myocardial infarction; cardiovascular illness.

**Corresponding author: E-mail: maryam043@gmail.com;*

1. INTRODUCTION

Myocardial infarction (MI) remains a leading cause of death worldwide. An acute MI happens when myocardial ischemia surpasses a basic edge, normally because of an intense plaque burst in the coronary courses, and the cell course of occasions overpowers myocardial cell fix systems prompting myocardial cell harm. Myocardial ischemia happens because of plaque develop in the coronary veins, officially known as atherosclerosis or coronary supply route illness (CAD) [1]. Breaking of weak atherosclerotic plaque follows a time of ceaseless plaque destabilization or potentially plaque development due to different patho-organic cycles. Plaque substances are encased inside a settling sinewy cap that forestalls openness of the thrombogenic center to the circulatory system, and debilitating of this cap can hence prompt plaque crack and MI [2].

Cardiovascular illness (CVD) is the main source of death around the world, which has turned into an overall general medical condition. Intense myocardial dead tissue (AMI) is a typical clinical basic disease [3]. Specifically, the ascent of reperfusion treatment essentially decreased mortality and worked on the anticipation of AMI. As of late, the job of low thickness lipoprotein thickness (LDL-C) in the pathogenesis of atherosclerosis (AS) has drawn in much consideration [4]. Nonetheless, an ever increasing number of clinical preliminaries have uncovered that in the wake of controlling for deterministic gamble factors like LDL-C, the gamble for coronary illness (CHD) stayed, while the expansion in fatty oils (TG) was essentially related with the expansion in mortality, the rate of myocardial localized necrosis (MI) and the repeat pace of coronary course illness [5].

1.1 Aim

The basic aim of the study is to analyse the low HDL levels as a major risk factor of acute myocardial infarction in Pakistan.

2. MATERIALS AND METHODS

This cross sectional study was conducted in Ghazi Khan Medical College and DHQ Hafizabad between June and November 2021. The review was led by the moral advisory group of the medical clinic. The information was gathered from 100 patients of the two sexes who visited the OPD of the medical clinic routinely. TC level in serum was estimated using the endpoint test technique. HDL-C and LDL-C were estimated utilizing the immediate test technique. Non-HDL-C not set in stone by deducting serum HDL-C from serum TC. With the expansion in TG level, the extent of individuals with a background marked by smoking expanded, weight file (BMI), SBP, DBP, FBG, UA and the pace of MI expanded, while HDL-C level step by step diminished, and the distinctions were all measurably huge. Contrasts in TC and LDL-C levels were not genuinely huge.

Data were entered into Epidata 3.0 and analysed using Statistical Package for Social Science (SPSS) version 20.0. Estimation information were communicated as mean ± standard deviation (SD). Intergroup examination was led utilizing investigation of fluctuation.

3. RESULTS

The information was gathered from 100 patients of the two sexes. The mean age was 45±5.46 years. The extent of male subjects was higher in bunches with high TG levels, while the distinction in age was not measurably critical.

4. DISCUSSION

In a broadly referred to meta-examination of four enormous investigations (absolute number of people contemplated: 15,252), a 1 mg/dL increment of HDL-C levels was accounted for to be related with a 2%-3% diminished CVD risk [6]. Niacin, by and by endorsed with a statin, is one of the most regularly involved pharmacological treatment pointed toward bringing HDL-C focuses up in patients with such dangers. At a pharmacological portion of ~1.5-2 g each day, Niacin is perhaps the most intense specialist accessible for this reason. Niacin likewise decreases all proatherogenic lipids and lipoproteins, including absolute cholesterol, TGs, exceptionally low-thickness lipoprotein, LDL, and lipoprotein [7]. Notwithstanding its prevalence, the viability of niacin has come into question in ongoing examinations. Two particular examinations, Atherosclerosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides and Impact on Global Health Outcomes (AIM-HIGH) and Heart Protection Study 2 - Treatment of High-thickness Lipoprotein to Reduce the Incidence of Vascular Events (HPS2-THRIVE) were pointed toward assessing whether adding the cutting edge, stretched out discharge niacin details to statin

Table 1. Socio-demographic values of selected patients [11]

Variables	Univariate		Multivariate	
	OR (95% CI)	***p* value**	**OR (95% CI)**	***p* value**
Age	1.01 (0.97–1.04)	0.75	1.01 (0.96–1.05)	0.79
Sex, male	0.66 (0.26–1.67)	0.38		
Body mass index	0.98 (0.89–1.09)	0.73		
Current smoking	1.63 (0.70–3.82)	0.26	2.46 (0.87–6.95)	0.090
Hypertension	0.77 (0.34–1.75)	0.53		
Diabetes mellitus	0.77 (0.37–1.58)	0.48	0.65 (0.27–1.58)	0.34
eGFR	0.99 (0.97–1.01)	0.48	0.98 (0.96–1.01)	0.22
LDL cholesterol	1.00 (0.99–1.02)	0.63		
HDL cholesterol	0.97 (0.93–1.00)	0.058		
HDL2 cholesterol	0.97 (0.92–1.02)	0.26		
HDL3 cholesterol	0.86 (0.76–0.98)	0.018	0.86 (0.74–0.99)	0.038
Triglyceride	1.00 (0.99–1.01)	0.16		
C-reactive protein	1.18 (0.90–1.54)	0.22		
Total stent length	1.06 (1.01–1.10)	0.011	1.04 (0.99–1.09)	0.16
Total inflation time	1.01 (1.00–1.01)	0.014	1.00 (0.99–1.01)	0.22

treatment gives steady advantage over statin treatment alone as far as cardiovascular essential occasions in patients with laid out CAD [8]. These clinical preliminaries concentrated on explicit populaces of stable ischemic coronary illness patients, barring patients with MI or those with critical remaining blended dyslipidemia not treated with ideal portions of serious statin treatment [9]. Both the AIM-HIGH and HPS2-THRIVE clinical preliminaries were halted rashly because of an absence of gainful impacts and a failure to meet essential endpoints of decreased cardiovascular illness and MI risk [10].

5. CONCLUSION

It is concluded that low HDL level is noted to be present in a high percentage of acute myocardial infarction patients and can be a major risk contributor.

CONSENT

As per international standard or university standard, patients' written consent has been collected and preserved by the author(s).

ETHICAL APPROVAL

As per international standard or university standard written ethical approval has been collected and preserved by the author(s).

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012;367:2089–2099.
2. Lincoff AM, Nicholls SJ, Riesmeyer JS, Barter PJ, Brewer HB, Fox KAA, et al. Evacetrapib and cardiovascular outcomes in high-risk vascular disease. N Engl J Med. 2017;376:1933–1942.
3. Ginsberg HN, Elam MB, Lovato LC, Crouse JR, Leiter LA, Linz P, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362: 1563–1574.
4. Kontush A, Chapman MJ. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol Rev. 2006;58: 342–374.
5. Kimura S, Sugiyama T, Hishikari K, Yamakami Y, Sagawa Y, Kojima K, et al. Association of Intravascular Ultrasound- and Optical Coherence Tomography-Assessed Coronary Plaque Morphology with Periprocedural Myocardial Injury in patients with stable angina pectoris. Circ J. 2015;79:1944–1953.
6. Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365:2255–2267.

7. Landray MJ, Haynes R, Hopewell JC, Parish S, Aung T, Tomson J, et al. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014; 371:203–212.
8. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357: 2109–2122.
9. Rosenson RS, Brewer HB Jr., Chapman MJ, Fazio S, Hussain MM, Kontush A, et al. HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. Clin Chem. 2011; 57:392–410.
10. Sharrett AR, Ballantyne CM, Coady SA, Heiss G, Sorlie PD, Catellier D, et al. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: the atherosclerosis risk in communities (ARIC) study. Circulation. 2001;104:1108–1113.
11. Harada K, Kikuchi R, Suzuki S, Tanaka A, Aoki T, Iwakawa N, Kojima H, Hirayama K, Mitsuda T, Sumi T, Negishi Y. Impact of high-density lipoprotein 3 cholesterol subfraction on periprocedural myocardial injury in patients who underwent elective percutaneous coronary intervention. Lipids in Health and Disease. 2018;17(1): 1-7.

© 2022 Mushtaq et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:
The peer review history for this paper can be accessed here:
https://www.sdiarticle5.com/review-history/85930